PHILADELPHIA -A new large population-based study from the Sidney Kimmel Cancer Center—Jefferson Health shows that novel oral androgen signaling inhibitor therapies are associated with an increased risk of death in patients ...
Aug 13, 2019
0
0
A combination of enzalutamide and androgen deprivation therapy (ADT) significantly reduced the risk of metastatic progression or death over time in men with advanced prostate cancer, according to the results of clinical trial ...
Jul 30, 2019
0
12
Cancer researchers at the University of Virginia School of Medicine have identified a key to controlling the growth and progression of prostate cancer, the second most common cancer in men. The researchers have dubbed this ...
Jul 29, 2019
0
18
Testing for genetic weaknesses in repairing DNA could pick out men who may benefit from a new type of targeted nuclear medicine, a new study reports.
Jul 23, 2019
0
3
Alzheimer's disease may be a risk for older prostate cancer patients given hormone-blocking treatment, a large, U.S. government-funded analysis found.
Jul 05, 2019
1
74
Today the New England Journal of Medicine published the first results of a phase III international clinical study called TITAN (National Clinical Trials Number 02489318), which evaluated the effectiveness and safety of a ...
Jun 03, 2019
0
9
A study published recently in the Journal of Clinical Oncology Precision Oncology, an American Society of Clinical Oncology (ASCO) journal, outlines findings from the largest-ever prospective genomic analysis of advanced ...
May 13, 2019
0
3
Scientists have identified a gene mutation in the tumours of men with prostate cancer that is linked to very poor survival—and which could be used to pick out patients for more intensive treatment.
May 06, 2019
0
49
Researchers at Karolinska Institutet in Sweden have identified blood-based biomarkers that may determine which patients will benefit from continued hormonal therapy for advanced prostate cancer. The results are published ...
May 03, 2019
0
69
A prostate cancer drug won't be offered on the NHS any earlier in the treatment plans of patients living with the disease in England, after it failed to pass a cost-effectiveness review.
Apr 08, 2019
0
2
